ライフサイエンスコーパス: long-acting

1 ould facilitate the rational design of novel long-acting A2A agonists with improved clinical efficacy

2 ort the use of cabotegravir plus rilpivirine long-acting administered every 2 months as a therapeutic

3 nd demonstrate the potential of GS-6207 as a long-acting agent to treat or prevent infection with HIV

4 , suggesting that it may have potential as a long-acting agent.

5 tial of ultrapotent capsid inhibitors as new long-acting agents for the treatment of HIV-1 infection.

6 Long-acting agents from new antiretroviral classes can p

7 Long-acting agonists reduce the number of injections, bu

8 in response to systemic administration of a long-acting analog of the gut-hormone glucagon-like pept

9 paracasei NFBC 338 transformed to express a long-acting analogue of GLP-1 or the isogenic control mi

10 th intensified treatment of midgut NETs with long-acting and repeatable octreotide, PRRT reduced the

11 ocal inactivation of KOR by injection of the long-acting antagonist nor-BNI in the ventral tegmental

12 Long-acting anti-HIV products can substantively change t

13 We further show that prototype long-acting anti-VEGF drugs (LAVAs) that include this pe

14 reated with once- or twice-daily maintenance long-acting anticholinergic and beta-agonist bronchodila

15 weed" highlight the public health impact of long-acting anticoagulant rodenticides (LAARs).

16 We previously showed long-acting antiresorptive zoledronic acid (ZOL) prevent

17 As such, there is strong interest in long-acting antiretroviral (ARV) agents that can be admi

18 gonists as a new class of immune-stimulating long-acting antiretroviral agents.

19 Long-acting antiretroviral implants could help protect h

20 Recommended for the first time, a long-acting antiretroviral regimen injected once every 4

21 NP; PC7A), in human PBMCs induces potent and long-acting antiretroviral response against several labo

22 is an investigational principal component of long-acting antiretroviral therapy.

23 Long-acting antiretrovirals could provide a useful alter

24 es, and are being considered as partners for long-acting antiretrovirals for use in therapy or preven

25 p towards improving treatment outcomes is in long-acting antiretrovirals.

26 rier encasement must be boosted to establish long-acting ARV depots.

27 epine days' supply, first prescription for a long-acting benzodiazepine, and recent prescription opio

28 t of rats with relevant therapeutic doses of long acting beta(2)AR agonist (LABA; clenbuterol; CLEN)

29 recommend that inhaled corticosteroid (ICS)/long-acting beta (2)-adrenoceptor agonist (LABA) combina

30 an bronchial epithelial cells, formoterol, a long-acting beta (2)-adrenoceptor agonist (LABA), enhanc

31 ated gene expression changes produced by the long-acting beta (2)-adrenoceptor agonists (LABAs) salme

32 and treated with inhaled corticosteroids, a long-acting beta agonist, and clarithromycin, but her co

33 corticosteroid, fluticasone furoate, and the long-acting beta agonist, vilanterol could improve survi

34 ogressive increase in inhaled corticosteroid/long-acting beta(2) agonist therapy to a maintenance inh

35 ed corticosteroid), formoterol fumarate (FF; long-acting beta(2) agonist), and glycopyrronium (G; lon

36 RAN: medium dose; TRIGGER: high dose) plus a long-acting beta(2) agonist.

37 nition used, our findings support the use of long-acting beta(2) agonists/long-acting muscarinic rece

38 onchoprotection (LOBP) with a regularly used long-acting beta(2)-adrenergic receptor agonist (LABA) i

39 To investigate the effect of ICS/long-acting beta(2)-agonist (LABA) treatment on both lun

40 s: 1) a strong recommendation for the use of long-acting beta(2)-agonist (LABA)/long-acting muscarini

41 Fe(NO)-low population when adherent with ICS/long-acting beta(2)-agonist (median, 26 ppb [interquarti

42 ic antagonist to inhaled corticosteroid plus long-acting beta(2)-agonist therapy improves lung functi

43 ed treatment with standard high-dose ICS and long-acting beta(2)-agonist treatment.

44 portant clinical benefits from optimized ICS/long-acting beta(2)-agonist treatment.

45 nhaled therapy (inhaled corticosteroids plus long-acting beta(2)-agonists or long-acting beta(2)-agon

46 teroids plus long-acting beta(2)-agonists or long-acting beta(2)-agonists plus long-acting muscarinic

47 nhaled therapy (inhaled corticosteroids plus long-acting beta(2)-agonists plus long-acting muscarinic

48 iple therapy with inhaled corticosteroid and long-acting beta-agonist (ICS/LABA).

49 olled asthma benefit more from addition of a long-acting beta-agonist (LABA) than from increased gluc

50 ropionate dose [<600 vs >/=600 mug/day], and long-acting beta-agonist [LABA] use [yes/no]).

51 ICS are prescribed at step 2 and within ICS/long-acting beta-agonist combination therapy at step 3.

52 ailable to prescribe higher doses within ICS/long-acting beta-agonist maintenance therapy in accordan

53 of fluticasone or greater with or without a long-acting beta-agonist versus 100 mug or less assigned

54 uticasone propionate (FLU) with or without a long-acting beta-agonist versus 100 mug or less of FLU i

55 Long-acting beta-agonists (LABAs) have been shown to inc

56 The safety of long-acting beta-agonists added to inhaled corticosteroi

57 remained uncontrolled despite treatment with long-acting beta-agonists and medium-to-high doses of in

58 Among patients treated with long-acting beta-agonists and medium-to-high doses of in

59 the mechanisms by which corticosteroids and long-acting beta2 -adrenergic agonists confer protection

60 rticosteroids alone or in combination with a long-acting beta2 -adrenergic receptor agonist (LABA) on

61 corticosteroids (ICS) or low-dosage ICS plus long-acting beta2 agonist fixed-combination therapy at s

62 ination drug of inhaled corticosteroid (ICS)/long-acting beta2 agonist is being used as a long-term c

63 , and others have shown that combinations of long-acting beta2-adrenergic agonists (LABAs) and long-a

64 Salmeterol is a long-acting beta2-adrenergic receptor agonist used to tr

65 S) and inhaled corticosteroids combined with long-acting beta2-agonist (ICS/LABA) are standard treatm

66 erapy with dual inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA) therapy in patients wit

67 steroids (ICSs) or ICSs + add-on medication (long-acting beta2-agonist [LABA], leukotriene receptor a

68 responsiveness to an inhaled corticosteroid/long-acting beta2-agonist combination versus a long-acti

69 Inhaled corticosteroids and long-acting beta2-agonist combinations are more effectiv

70 ed corticosteroid fluticasone propionate and long-acting beta2-agonist salmeterol xinafoate, which ar

71 l/glycopyrronium 110/50 mug with twice-daily long-acting beta2-agonist/inhaled corticosteroid salmete

72 cerbations) study, which compared once-daily long-acting beta2-agonist/long-acting muscarinic antagon

73 ng-acting beta2-agonist combination versus a long-acting beta2-agonist/long-acting muscarinic antagon

74 The use of inhaled long-acting beta2-agonists alone is not appropriate.

75 erapy, including inhaled corticosteroids and long-acting beta2-agonists, is effective in patients for

76 We recently reported the development of a long-acting, bifunctional MOR agonist/delta-opioid recep

77 ected patients is through the development of long-acting biologic inhibitors.

78 dnectins targeting CD4 and gp41, a potential long-acting biologic, GSK3732394, was developed with thr

79 These long-acting BMS-806 analogues may facilitate enrichment

80 sinophil count, compared with a non-ICS dual long-acting bronchodilator (umeclidinium-vilanterol n=20

81 for the efficacy of triple therapy with two long-acting bronchodilators and an inhaled corticosteroi

82 Other controller medications, such as long-acting bronchodilators and biologics, may be requir

83 Several studies have documented that long-acting bronchodilators can reduce exacerbation rate

84 for or against ICS as an additive therapy to long-acting bronchodilators in patients with COPD and bl

85 enefit of LABA/LAMA combinations over single long-acting bronchodilators or LABA/inhaled corticostero

86 Long-acting cabotegravir (CAB LA) is a potential new inj

87 V) transmission model to investigate whether long-acting cabotegravir (CAB LA) prevents penile SHIV a

88 rt to understand the factors associated with long-acting cabotegravir (GSK1265744 LAP) pharmacokineti

89 gravir plus rilpivirine at 4-week intervals (long-acting cabotegravir 400 mg plus rilpivirine 600 mg;

90 g; two 2 mL injections) or 8-week intervals (long-acting cabotegravir 600 mg plus rilpivirine 900 mg;

91 ssessment, three intramuscular injections of long-acting cabotegravir 800 mg or saline placebo at 12

92 rse events was higher in participants in the long-acting cabotegravir group (n=75 [80%]) than in thos

93 afety, tolerability, and pharmacokinetics of long-acting cabotegravir injections in healthy men not a

94 e randomly assigned (2:2:1) to intramuscular long-acting cabotegravir plus rilpivirine at 4-week inte

95 The two-drug combination of all-injectable, long-acting cabotegravir plus rilpivirine every 4 weeks

96 The LATTE-2 study evaluated long-acting cabotegravir plus rilpivirine for maintenanc

97 Therapy with long-acting cabotegravir plus rilpivirine was noninferio

98 or 1 month followed by monthly injections of long-acting cabotegravir plus rilpivirine.

99 , mild-to-moderate injection-site reactions, long-acting cabotegravir was well tolerated with an acce

100 cluding a diuretic, usually thiazide-like, a long-acting calcium channel blocker, and a blocker of th

101 Long-acting central sympatholytic drugs are the mainstay

102 ble microneedle patch for self-administered, long-acting contraception could enable women to better c

103 Mexico was the only country in which long-acting contraceptive methods were more frequently u

104 d Tobago had more than 10% of women adopting long-acting contraceptive methods.

105 We developed a long-acting DAA system (LA-DAAS) capable of prolonged do

106 Injectable, long-acting depot formulations based on poly(lactide-co-

107 (PLGA) has been used for making injectable, long-acting depot formulations for the last three decade

108 de) (PLGA) has been used in many injectable, long-acting depot formulations.

109 al efficacy of cabotegravir plus rilpivirine long-acting dosed every 8 weeks with that of every 4 wee

110 torage for global health and developed world long-acting drug delivery applications.

111 Injectable, long-acting drug delivery systems provide effective drug

112 er investment in research and development of long-acting drugs with dual activity against HIV and HBV

113 luation of polydimethylsiloxane (PDMS) based long-acting (e.g. 3-5 years) levonorgestrel (LNG) intrau

114 1:1 to receive cabotegravir plus rilpivirine long-acting every 8 weeks or every 4 weeks.

115 Cabotegravir plus rilpivirine long-acting every 8 weeks was non-inferior to dosing eve

116 In November 2017, the Long acting/Extended Release Antiretroviral Resource Pro

117 oviral drug rilpivirine was developed into a long-acting formulation (RPV LA) to improve adherence fo

118 As a long-acting formulation of the nonnucleoside reverse tra

119 ghlighting the need for novel approaches and long-acting formulations as PrEP roll-out expands.

120 The first long-acting formulations of HIV drugs are undergoing reg

121 EP regimen, including currently investigated long-acting formulations, or patent-expired drugs.

122 Injectable long-acting formulations, specifically poly(lactide-co-g

123 Despite the benefits of using this type of long-acting formulations, the development of clinical pr

124 ctating women are considered when developing long-acting formulations.

125 using daily pills, which could be reduced by long-acting formulations.

126 rotein hormone thyrostimulin and design of a long-acting FSH.

127 Osocimab is a long-acting, fully human monoclonal antibody that inhibi

128 mary pituitary cultures using forskolin or a long-acting GH-releasing hormone (GHRH) analog increased

129 In vivo long-acting GHRH treatment also induced pituitary DNA da

130 ears or older, all of whom were treated with long-acting (glargine, detemir) or neutral protamine Hag

131 in combination with our previously reported long-acting GLP-1 analog is demonstrated in a diet-induc

132 The clinical efficacies of long-acting GLP-1 derivatives strongly support discovery

133 Liraglutide, a long-acting GLP-1 receptor agonist, is approved for trea

134 stration of a peripheral CB1R inhibitor with long-acting GLP-1R agonists achieves greater reduction i

135 Exendin-4 is a long acting glucagon-like peptide 1 (GLP-1) analogue tha

136 improved therapeutic potential owing to its long-acting glycemic control with improved cardiovascula

137 ial, from both the oral standard-of-care and long-acting groups, must have completed the 52-week comp

138 Access to long-acting HIV drug formulations with dual activity aga

139 cakin (pegylated IL-10) is a first-in-class, long-acting IL-10 receptor agonist that induces oligoclo

140 Long-acting IL-4 complex (IL-4c; recombinant IL-4 mixed

141 Slow-release, long-acting, implantable naltrexone might improve these

142 mining the final efficacy outcomes, and both long-acting implants and injectable depot systems are be

143 every 4 weeks cabotegravir plus rilpivirine long-acting in ATLAS.

144 While cabotegravir (CAB) long-acting injectable (CAB LA), an integrase strand tra

145 zapine (HR, 0.58; 95% CI, 0.53-0.63) and all long-acting injectable antipsychotic medications (HRs 0.

146 Long-acting injectable antipsychotic medications were as

147 Clozapine and long-acting injectable antipsychotic medications were th

148 Long-acting injectable antiretroviral (LA-ARV) drugs wit

149 isk for HIV, were randomly assigned (3:1) to long-acting injectable cabotegravir (800 mg given three

150 ur findings support further investigation of long-acting injectable cabotegravir as an alternative to

151 e to lower limit of quantification (LLOQ) of long-acting injectable cabotegravir during the injection

152 erminal phase pharmacokinetics and safety of long-acting injectable cabotegravir in participants incl

153 Long-acting injectable cabotegravir is a novel integrase

154 A long-acting injectable formulation of the HIV integrase

155 e are antiretroviral drugs in development as long-acting injectable formulations.

156 GS-CA1 showed high antiviral efficacy as a long-acting injectable monotherapy in a humanized mouse

157 phenazine (HR, 0.58; 95% CI, 0.52-0.65), and long-acting injectable olanzapine (HR, 0.58; 95% CI, 0.4

158 lowest during monotherapy with once-monthly long-acting injectable paliperidone (hazard ratio [HR],

159 7), clozapine (HR, 0.53; 95% CI, 0.48-0.58), long-acting injectable perphenazine (HR, 0.58; 95% CI, 0

160 Long-acting injectable regimens may simplify therapy for

161 italization is about 20% to 30% lower during long-acting injectable treatments compared with equivale

162 hazard ratio [HR], 0.51; 95% CI, 0.41-0.64), long-acting injectable zuclopenthixol (HR, 0.53; 95% CI,

163 ntipsychotic drugs and haloperidol (oral and long-acting injectable, LAI) in people with acute schizo

164 ide and islatravir [also known as MK-8591]), long-acting injectables (eg, cabotegravir), vaginal ring

165 y regulatory bodies and availability, with a long-acting injection given every 8 weeks.

166 Long-acting injection naltrexone (XR-naltrexone), admini

167 apine, paliperidone, quetiapine, risperidone long-acting injection, valproate, and placebo).

168 Purpose The association between long-acting insulin analogs and increased breast cancer

169 95% CIs of incident breast cancer, comparing long-acting insulin analogs with NPH overall, as well as

170 In vivo, daily administration of marketed long-acting insulin, glargine, resulted in fluctuating b

171 o describe reimbursement and market share of long-acting insulins before and after approval of new in

172 3 clinical studies showed non-inferiority of long-acting intramuscular cabotegravir and rilpivirine d

173 results of the first phase 3 trial assessing long-acting intramuscular pasireotide in patients with C

174 In Experiment 4, administration of the long-acting KOR antagonist nor-BNI into the central nucl

175 This study showed that the long-acting KOR antagonists are affected by both the sex

176 As a treatment alternative, long-acting (LA) antiretrovirals can sustain therapeutic

177 Cabotegravir and rilpivirine are 2 long-acting (LA) antiretrovirals that can be administere

178 Long-acting (LA) ARV formulations or delivery systems th

179 Long-acting (LA) depot injections of nanomilled poorly w

180 e experiments comparatively investigated the long-acting (LA) PrEP potency of subcutaneous (SubQ) adm

181 The aim of this study was to evaluate if long-acting (LA) SSA treatment changes the uptake of (68

182 Appropriate use of long-acting maintenance bronchodilators, inhaled cortico

183 ority study of cabotegravir plus rilpivirine long-acting maintenance therapy administered intramuscul

184 dicine/telehealth, along with broader use of long-acting medications for the treatment of human immun

185 contraceptive services, including short- and long-acting methods, are available, even in protracted c

186 men will use modern contraception, including long-acting methods.

187 Thus, long-acting mIL-2/CD25 represents an improved IL-2 analo

188 d users of individual long-acting opioids to long-acting morphine users (considered the prototypical

189 Tiotropium is a long acting muscarinic antagonist (LAMA), licensed as tr

190 he use of long-acting beta(2)-agonist (LABA)/long-acting muscarinic antagonist (LAMA) combination the

191 receptor antagonist [LTRA], theophylline, or long-acting muscarinic antagonist [LAMA]) steadily incre

192 mbination versus a long-acting beta2-agonist/long-acting muscarinic antagonist combination for exacer

193 ompared once-daily long-acting beta2-agonist/long-acting muscarinic antagonist indacaterol/glycopyrro

194 In uncontrolled asthma, addition of a long-acting muscarinic antagonist to inhaled corticoster

195 ing beta(2) agonist), and glycopyrronium (G; long-acting muscarinic antagonist) with the combination

196 e (an inhaled glucocorticoid), tiotropium (a long-acting muscarinic antagonist), or placebo.

197 Other controller approaches include long-acting muscarinic antagonists (eg, tiotropium), and

198 acting beta2-adrenergic agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) provide great

199 Add-on long-acting muscarinic antagonists are recommended in in

200 There is concern that long-acting muscarinic antagonists increase cardiovascul

201 .68), and the odds ratio for prescription of long-acting muscarinic antagonists was 2.27 (95% CI = 1.

202 gonists or long-acting beta(2)-agonists plus long-acting muscarinic antagonists) or triple inhaled th

203 roids plus long-acting beta(2)-agonists plus long-acting muscarinic antagonists).

204 sthma treatment and the ratio of those using long-acting muscarinic receptor antagonist were higher t

205 port the use of long-acting beta(2) agonists/long-acting muscarinic receptor antagonists as the prefe

206 Long-acting naltrexone showed positive advantage on prev

207 Moreover, a long-acting nanoformulation of compound I [compound I na

208 erase (hAChE), yielding short-, medium-, and long-acting nanomolar hBChE inhibitors (with a half-life

209 Laninamivir (LAN) is a long-acting neuraminidase (NA) inhibitor (NAI) with a si

210 only prescribed calcium channel blockers and long-acting nitrates at discharge (DM versus not: 27.9%

211 development of novel medical treatments (eg, long-acting octreotide formulations, mTOR inhibitors, an

212 Long-acting octreotide treatment diminished (68)Ga-DOTAT

213 escribers (OR 2.23 95% CI 1.75-2.83) and new long acting opioid prescriptions (OR 1.69, 95% CI 1.05-2

214 oid and/or benzodiazepine prescriptions, new long acting opioid prescriptions, or new dose escalation

215 serious infection among patients initiating long-acting opioid analgesics with and without previousl

216 Maintaining addicted pregnant women on long-acting opioid receptor agonist is the most common s

217 The risk of serious infections among long-acting opioid users varies by opioid type.

218 risk was due to out-of-hospital deaths (154 long-acting opioid, 60 control deaths; HR, 1.90; 95% CI,

219 Medicaid enrollees age >=18 years initiating long-acting opioids (1995-2015).

220 We also analysed prescriptions for long-acting opioids at high doses.

221 We further compared users of individual long-acting opioids to long-acting morphine users (consi

222 pare the infection risk among patients using long-acting opioids with known immunosuppressive propert

223 ) to the infection risk among patients using long-acting opioids without known immunosuppressive prop

224 ch agenda and promoting early development of long-acting or extended release products for key populat

225 uble drugs and may enable the development of long-acting oral therapies for a wide variety of conditi

226 cies, resulting in a PK profile suitable for long-acting parenteral administration.

227 Thus, implantable devices and long-acting parenteral prodrugs have emerged which may p

228 Long-Acting Parenterals (LAPs) have been used in the cli

229 study, we prepared and characterized a very long-acting PARP inhibitor.

230 y assigned (1:1:1) to receive treatment with long-acting pasireotide (60 mg intramuscularly every 28

231 e aimed to assess the efficacy and safety of long-acting pasireotide and everolimus, administered alo

232 41 patients (39.0%, 95% CI 24.2-55.5) in the long-acting pasireotide group, 14 of 42 patients (33.3%,

233 in nine countries: 41 were allocated to the long-acting pasireotide group, 42 to the everolimus grou

234 eatment exposure date: two (5%) of 41 in the long-acting pasireotide group, six (14%) of 42 in the ev

235 Long-acting pasireotide is an efficacious treatment opti

236 rse events with a suspected association with long-acting pasireotide monotherapy were diarrhoea (15 [

237 rse events with a suspected association with long-acting pasireotide monotherapy were gamma-glutamylt

238 INTERPRETATION: Long-acting pasireotide normalised mUFC concentration in

239 No deaths were suspected to be related to long-acting pasireotide treatment.

240 c parameters of TLZ in humans, we designed a long-acting PEG~TLZ for humans that may be superior in e

241 Currently, the long-acting pegylated form (pegasparaginase) is the only

242 ow that systemically administering a potent, long-acting PEGylated TRAIL (TRAILPEG) is profoundly ant

243 Here, we demonstrate that a long-acting, pegylated analog of the NT peptide (P-NT) r

244 Thus, our results suggest that the long-acting, peripherally restricted OTR agonist may off

245 Various ongoing trials seek to evaluate long-acting pre-exposure prophylaxis (PrEP) agents by sh

246 se selection for the development of bNAbs as long-acting pre-exposure prophylaxis candidates for use

247 ngs demonstrate that a single injection of a long-acting prodrug of the PARP inhibitor talazoparib in

248 uld focus not only on how best to transition long-acting products to these populations, but also on e

249 We offer an alternative standard for long-acting products-a measure of the effectiveness of t

250 Antiretroviral agents with long-acting properties have potential to improve treatme

251 croscopy structure of human PTH1R bound to a long-acting PTH analog and the stimulatory G protein.

252 e proportion with viral suppression for each long-acting regimen is not worse than the oral regimen p

253 At 32 weeks following randomisation, both long-acting regimens met primary criteria for comparabil

254 long-term release profiles, providing viable long-acting release (LAR) alternatives to the LD.

255 on-free survival versus high-dose octreotide long-acting release in a phase III clinical trial of wel

256 us best supportive care including octreotide long-acting repeatable [LAR] administered intramuscularl

257 E PET/CT scanning before and after receiving long-acting repeatable octreotide (Sandostatin LAR) were

258 We describe the design and testing of a long-acting reservoir subcutaneous implant capable of re

259 pitals for provision of immediate postpartum long-acting reversible contraception (IPP-LARC) separate

260 Long-acting reversible contraception (LARC) is among the

261 male recipients should receive advice to use long-acting reversible contraception and avoid pregnancy

262 on promotion of contraception, particularly long-acting reversible contraception and dual method con

263 The importance of discussing long-acting reversible contraception before and after pr

264 (OCPs) compared to women using injectable or long-acting reversible contraception methods (OCP 28% ve

265 included city, younger age, lower education, long-acting reversible contraception usage, Trichomonas

266 re than half of 15-19-year-olds were using a long-acting reversible contraceptive (LARC; 51.7%, 95% C

267 Although long-acting reversible contraceptives (implants, intraut

268 implants and intrauterine devices (IUDs) are long-acting reversible contraceptives (LARCs) that are k

269 Long-acting reversible contraceptives are seldom used in

270 e, and ease of continuation, availability of long-acting reversible contraceptives should be expanded

271 Use of long-acting reversible contraceptives was below 10% in 1

272 out education showed particularly low use of long-acting reversible contraceptives.

273 raception, despite the high effectiveness of long-acting reversible contraceptives.

274 ouse model of HIV-1 infection, outperforming long-acting rilpivirine.

275 Inclisiran (ALN-PCSsc) is a long-acting RNA interference (RNAi) therapeutic agent th

276 Irbesartan, a long acting selective angiotensin-1 receptor inhibitor,

277 ic inhibitor could allow it to function as a long-acting self-administered treatment for patients wit

278 raceptive use by type of contraception used (long-acting, short-acting, or permanent).

279 Here, sequential long-acting slow-effective release antiviral therapy (LA

280 y provides a means to extend the action of a long-acting, slow, effective release of antiretroviral t

281 (68)Ga-DOTATATE uptake before treatment with long-acting somatostatin analogs differs from that after

282 are modestly augmented by the addition of a long-acting ss-agonist.

283 The availability of such long-acting stabilizers of Env shape will allow the natu

284 A group of peptide-based, long-acting, stable, highly selective cholecystokinin 1

285 potentially could be self-administered as a long-acting subcutaneous injection.

286 Long-acting sustained intraocular drug delivery provides

287 h prolonged PrEP efficacy, thus establishing long-acting TAF + FTC NPs as a potential PrEP modality.

288 We show that long-acting TAF depots can be designed as block copolyme

289 ed in 11% and 2%, respectively, who received long-acting therapy and in 4% and 1% who received oral t

290 in 6 of 283 participants (2.1%) who received long-acting therapy and in 7 of 283 (2.5%) who received

291 r at week 48 was found in 93.6% who received long-acting therapy and in 93.3% who received oral thera

292 itched to long-acting therapy; 91% preferred long-acting therapy at week 48.

293 ons of HIV capsid protein and is amenable to long-acting therapy owing to its high potency, low in vi

294 Of the participants who received long-acting therapy, 86% reported injection-site reactio

295 ion increased after participants switched to long-acting therapy; 91% preferred long-acting therapy a

296 ive agents of different classes, including a long-acting thiazide-like diuretic and an MR (mineraloco

297 te that MCAM could be a safe, effective, and long-acting treatment for OUD.

298 Here we report an ultra-long-acting tunable, biodegradable, and removable polyme

299 only LTB(4) was at least as effective as the long-acting variant that inhibited both C5 and LTB(4), p

300 ore efficacious in mouse EAU models, and the long-acting variant that inhibited only LTB(4) was at le